

A Genetic Programming-based Regression for Extrapolating a Blood Glucose-Dynamics Model from Interstitial Glucose Measurements and their First Derivatives

I. De Falco^a, A. Della Cioppa^{b,*}, A. Giugliano^b, A. Marcelli^b, T. Koutny^c,
M. Krcma^d, U. Scafuri^a, E. Tarantino^a

^aICAR, National Research Council of Italy, Via P. Castellino 111, Naples, Italy

^bNCLab, DIEM, University of Salerno, Via Giovanni Paolo II 132, Salerno, Italy

^cNTIS – New Technologies for the Information Society, Faculty of Applied Sciences,
University of West Bohemia, Univerzitni 8, Pilsen 306 14, Czech Republic

^dDiabetology Center, First Dept. of Internal Medicine, Pilsen University Hospital, Alej
Svobody 80, Pilsen 306 54, Czech Republic

Abstract

This paper illustrates the development and the applicability of an Evolutionary Computation approach to enhance the treatment of Type-1 diabetic patients that necessitate insulin injections. In fact, being such a disease associated to a malfunctioning pancreas that generates an insufficient amount of insulin, a way to enhance the quality of life of these patients is to implement an artificial pancreas able to artificially regulate the insulin dosage. This work aims at extrapolating a regression model, capable of estimating the blood glucose (BG) through interstitial glucose (IG) measurements and their first derivative. Such an approach represents a viable preliminary stage in building the basic component of this artificial pancreas. In particular, considered the high complexity of the reciprocal interactions, an evolutionary-based

*Corresponding author. email: adellacioppa@unisa.it

¹This paper is an extended, improved version of the paper “An evolutionary approach for estimating the blood glucose by exploiting interstitial glucose measurements” presented at AI4Health 2018 workshop and published in: BIOSTEC 2018, Proceedings of the 11th International Joint Conference on Biomedical Engineering Systems and Technologies, Volume 5: HEALTHINF, Funchal, Madeira, Portugal, 19-21 January, 2018, pp. 625-632, ISBN: 978-989-758-281-3, INSTICC, 2018.

Preprint submitted to Applied Soft Computing

Published as:

De Falco, I., Della Cioppa, A., Giugliano, A., Marcelli, A., Koutny, T., Krcma, M., Scafuri, U., Tarantino, E. (2019). A genetic programming-based regression for extrapolating a blood glucose-dynamics model from interstitial glucose measurements and their first derivatives. APPLIED SOFT COMPUTING, vol. 77, p. 316-328, ISSN: 1568-4946, doi: 10.1016/j.asoc.2019.01.020.

strategy is outlined to extrapolate a mathematical relationship between BG and IG and its derivative. The investigation is carried out about the accuracy of personalized models and of a global relationship model for all of the subjects under examination. The discovered models are assessed through a comparison with other models during the experiments on personalized and global data.

Keywords:

Blood glucose estimation, Interstitial glucose, Regression models, Genetic Programming.

1. Introduction

Diabetes mellitus (DM) is a metabolic life-long disease characterized by inadequate control of blood glucose concentration in the body that induces a high (hyperglycemia) or a low (hypoglycemia) blood glucose (BG) level over a prolonged period. The glucose amount in the blood is regulated primarily by two hormones produced by the pancreas, i.e, insulin and glucagon, that indirectly affect the blood glucose concentration by lowering it (insulin) or by increasing it (glucagon). Insulin is essential for the conversion of glucose into energy utilized by cells after a food intake when there is an increase in glucose concentration. In absence of insulin, increased concentration of glucose in blood and interstitial fluid, if left untreated, can entail complications, such as the damage and the eventual failure of certain parts of multiple organs or even graver side effects like an increased risk of cardiac heart dysfunctions and failures, and stroke [1, 2, 3]. Instead the glucagon and hepatic production of glucose prevent the glucose concentration from decreasing substantially between meals or during the sleep. The control of this concentration allows avoiding complications as headache, hunger, difficulty in sleeping or more serious consequences like loss of consciousness, seizure and even coma. All these medical problems have a substantial impact on quality and on expectancy of life.

Diabetes is a worldwide growing phenomenon [4]. Since there is currently no cure, such a disease requires daily care and it is extremely important that the patients learn to effectively manage this condition to enhance their quality of life. Diabetic patients must be informed about the disease, instructed towards an appropriate diet, new hygiene habits, and taught about devised therapy and available medical devices, and drugs.

27 The diabetes is categorized in three major types: Type 1, Type 2 and
28 gestational diabetes. With DM Type 1, there is a complete lack of insulin as
29 pancreas fails to generate it. With DM Type 2, patient presents an insulin re-
30 sistance as cells necessitate an increment in insulin to operate appropriately.
31 With gestational diabetes, insulin resistance is coupled with an insulin se-
32 cretory defect. The insulin secretion is too low to comply with the increased
33 requests activated by the insulin resistance.

34 Within this paper the focus is on Type-1 DM or insulin-dependent dia-
35 betes, characterized by an autoimmune destruction of the insulin produced
36 by the pancreatic β -cells. The patients affected by such a chronic disorder
37 are subject to a progressive insulin deficiency and a resultant hyperglycemia,
38 and are totally dependent on an external injection of insulin to regulate their
39 blood-glucose concentration. This regulation is one of the most challenging
40 control problems to tackle in biomedical engineering. Hence, a methodology
41 able to attain a BG estimation as precise as possible assumes a very
42 crucial role to establish the appropriate rate of insulin to infuse.

43 Proper treatments to control the blood concentration and prevent the
44 complications associated to high BG levels last for many years and the related
45 social costs are very high.

46 Several invasive estimation devices are present on the market that take
47 BG measures in intervals that range from about 15 minutes to a couple of
48 hours with no measurements taken during the night. Patients are reluctant
49 to be subject to this continuous invasive BG control because of the related
50 pain. Hence, it can become difficult to suitably take care of the sick persons.
51 For such a reason, we need a methodology that obtains continuous BG esti-
52 mations by using minimally invasive devices. This possibility is offered by the
53 minimally invasive Continuous Glucose Monitoring System (CGMS) devices
54 that in a simpler way measure the IG, i.e., the glucose in the subcutaneous
55 tissue [5].

56 CGMS are portable devices capable of measuring glycemic levels indi-
57 rectly from the interstitial space almost continuously for several days with a
58 prefixed frequency. However, CGM sensors are affected by distortion due to
59 the glucose diffusion process across capillary wall between blood and intersti-
60 tial fluid, and by the time-by-time-varying systematic under/over-estimations
61 due to calibrations, sensor drifts and measurement noise [6, 7]. Most of these
62 devices need to be calibrated - to convert the measured electric current to
63 glucose level. Patient has to calibrate at least two times a day, when BG and
64 IG are steady. At this time, both levels can be considered as equal and thus

65 CGMS knows what quantity of electric current equals BG. Despite the fact
66 that more and more accurate devices are explored [8, 9], errors in sensors
67 calibration cause the measure inaccuracy of CGMS with respect to BG.

68 Although IG is not reckoned as a perfect BG indicator, nevertheless it is
69 the only system that permits large number of continuous and non-invasive
70 measurements a day. However, the complexity of the relationship between
71 glucose dynamics in BG and IG is far too complex to be acquired by the
72 calibration algorithms relying on simple linear regression techniques imple-
73 mented in current CGMS devices [10, 11]. In fact, CGMS is a low-power
74 device that implies low computational capacities and this invalidates the ac-
75 curacy of the measurements.

76 Considered that BG and IG can be significantly different due to physi-
77 ological reasons, the availability of a large amount of IG measures is highly
78 advisable to acquire as much as possible of the BG-to-IG dynamics. In fact,
79 significant progresses with CGMS and insulin pumps have allowed CGMS
80 data to be utilized to regulate insulin delivery [12].

81 Several analytical models have been suggested attempting to infer a math-
82 ematical relationship of IG and BG, as shown in Sect. 2. All these models
83 represent a basic step to design and implement an *artificial pancreas* (AP)
84 [13], i.e., an artificial device capable of automatically regulating insulin in-
85 jections according to the patients' needs so to ensure them a satisfactory
86 quality of life. This device must be capable of performing a glycemic control
87 by estimating BG values through the analysis of the IG signal. Reliable pre-
88 diction based on IG only is still beyond the reach since current algorithms
89 are based on supplemental, defective information such as an assessment of
90 carbohydrate intake by the patient.

91 The paper is a revised and extended version of a conference paper [14].
92 In particular, a more thorough review of the related works and additional
93 experimentations are included. The aim is to discover a law able to estimate
94 BG values by using IG measurements and their derivative. This law could
95 be the core of the knowledge base of an AP. These estimation problems are
96 known as *regression problems*. Considered the complexity of inducing an
97 analytical model, we leverage the ability of the Genetic Programming (GP)
98 [15] in tackling regression problems [16] to detect an efficient approximation
99 of the relationship between BG and IG values and their first derivative. The
100 experimental phase is carried out over a real-world database including both
101 BG and IG measures for several Type-1 diabetic subjects.

102 The paper is organized as follows. In Sect. 2 a review of the relevant re-

103 lated work is given. Section 3 describes the proposed genetic-based approach.
104 A discussion and a comparison with other models on the results attained on
105 personalized and global data is shown in Sect. 4. Conclusions and future
106 work are exposed in Sect. 5.

107 **2. Related research**

108 Numerous mathematical, statistical and analytical models focused on dif-
109 ferent aspects of diabetes, ranging from molecular and cellular biology, to
110 clinical science and to health service research have been developed. Several
111 of these modeling approaches aimed at discovering a reciprocal relationship
112 between BG and IG values.

113 The first, and most widely used, model striving to correlate BG and IG
114 was devised by Steil and Rebrin (SR) in 1999 [17]. It is represented by the
115 following equation:

$$b(t) = \frac{\tau}{g} \cdot \frac{di(t)}{dt} + \frac{1}{g} \cdot i(t) \quad (1)$$

116 where $b(t)$ and $i(t)$ are the BG and the IG at time t , and the parameters g
117 and τ represent the steady-state gain and the IG equilibration time constant,
118 respectively. An important task is the estimation of the best possible values
119 for g and τ so to enhance the model precision.

120 Hovorka et al. [18] developed a nonlinear predictive model to preserve
121 normoglycemic Type-1 diabetic patients during fasting conditions such as
122 during overnight fast. The controller employs Bayesian parameter estimation
123 to find time-varying model parameters. The predictive capabilities of the
124 model have been assessed using data from clinical trials for Type 1 diabetic
125 subjects.

126 Makroglou et al. [19] outlined an overview of several mathematical models
127 in literature aimed at describing the glucose-insulin regulatory system with
128 reference to DM. These models ranged from ordinary differential equations
129 to partial differential equations, to delay differential equations to the integro-
130 differential ones.

131 Dua et al. [20] presented a model-based control technique for regulating
132 the blood glucose level for Type-1 DM patients. The optimal insulin delivery
133 rate is attained off-line as an explicit function of the current blood glucose
134 concentration of the patient by using parametric programming algorithms.

135 Kildegaard et al. [21] proposed a physiological model relying on an in-
136 sulin, a meal and a glucose metabolism model coupled with a Monte Carlo

137 simulation to predict blood glucose values of diabetic people. Simulations
138 displayed how the variance coefficient for the different model compartments
139 changes over time. For diabetic people the inaccuracies of blood glucose
140 meters and carbohydrate estimates contribute to more than half of the vari-
141 ance. Therefore, the blood glucose prediction is strictly influenced by the
142 inaccuracy in the input variables and by the metabolic oscillations so that
143 an effective prediction model was very arduous to derive.

144 Facchinetti et al. [22] investigated the reconstruction of plasma glucose
145 from interstitial glucose taken through CGM sensors. Six diabetic volunteers
146 were monitored for two days using a minimally invasive device that returns
147 interstitial glucose concentration on the basis of an initial calibration pro-
148 cedure. At the same time, plasma glucose concentration was also measured
149 every 15 minutes. A nonparametric regularization deconvolution method
150 was used to reconstruct blood values from IG. The findings proved that the
151 quality of the reconstruction was unsatisfactory. Only after a recalibration
152 procedure the relative error in reconstructing blood glucose was significantly
153 reduced.

154 Leal et al. [23] monitored 18 patients for three days, and extracted the
155 relationship between the IG measured by CGMS and BG by employing an
156 autoregressive model. This resulted in 98.5% of the points being in A and B
157 zones of the Clarke error grid analysis [24].

158 Pérez-Gandía [25] harnessed an artificial neural network for the prediction
159 of the blood glucose concentration. The network received as inputs the CGM
160 sensor measurements during the preceding 20 minutes and returned as output
161 the prediction of glucose concentration at the selected prediction horizon
162 time. The tool accuracy was estimated by using the root mean square error
163 and the prediction delay.

164 Koutny [26] suggested a method to assess the BG-to-IG delay based on the
165 hypothesis that the change in the blood glucose level contains information
166 about the estimated rate with which the hypothalamus expects the blood
167 glucose level to return to its normal range. The same author advanced a
168 model of glucose dynamics that allows IG prediction [27]. By accounting the
169 delay, it was possible to relate the present BG and IG to future IG through
170 coefficients of the proposed model of glucose dynamics. An improvement in
171 the devised model of glucose dynamics to reduce its calculation error, espe-
172 cially with rapid changes of BG and IG, e.g., due to short-action insulin, is
173 proposed in [28]. This model is based on biological considerations, as for
174 example the importance of capillaries and the fact that capillaries in differ-

175 ent compartments have different permeabilities. Through the recommended
176 model tested on hyperglycemic-clamp data, he succeeded in achieving an
177 improved model to calculate the BG levels.

178 Del Favero et al. [29] investigated a new model that attempts to improve
179 that by Steil and Rebrin. Substantially, they reckoned that the value of g is
180 equal to 1, and added a way to calibrate the model so that a true IG can be
181 restored.

182 All the above analytic models present the optimization problem of es-
183 timating several parameters. This estimation is usually carried out by ex-
184 ploiting mathematical, biological or physiological considerations, or also by
185 performing an a-posteriori manual tuning. However, despite the lavished ef-
186 forts, an imbalance still remains between the current knowledge attained from
187 experimental approaches and their modeling. To overcome this problem, it
188 is important to revisit the progress made so far toward diabetes modeling.

189 In the last years some attempts based on evolutionary algorithms have
190 been performed for deriving diabetes modeling by using as inputs the values
191 measured by a GCMS as well as also previous and estimated future car-
192 bohydrate intakes and insulin injections [13]. Moreover, there has been an
193 increased interest in the development and application of methods relying on
194 artificial intelligence as decision support systems in diabetes management
195 and knowledge acquisition [30].

196 Evolutionary techniques have been also used for automatically excerpting
197 the parameter estimation of diabetes modeling. Koutny [31] combined the
198 analytic method proposed in [28] with meta-Differential Evolution. Namely,
199 starting from a continuously measured level of IG for human Type-1 diabetic
200 patients, he computed a continuous BG level. Six different scenarios were
201 employed to guarantee robust validation of the calculation, and a Differential
202 Evolution (DE) [32] was used to evaluate the parameters for the model in all
203 the scenarios. All the six scenarios, even the simplest ones, presented better
204 performance than CGMS in estimating BG values.

205 De Falco et al. [33, 34] proposed evolutionary-based tools to estimate the
206 BG values harnessing the easily available IG values. Relationships under the
207 form of explicit mathematical expressions were extracted. The experimen-
208 tation was carried out on a real-world database containing Type-1 diabetic
209 subjects. The comparison against state-of-the-art models stated the effective-
210 ness of the suggested evolutionary approaches. By considering lessons learned
211 in [35], De Falco et al. [36] investigated the ability of evolutionary-based al-
212 gorithms in finding relationships between IG and BG values for telemedicine

213 purposes. The paper represents a precursory steps towards the deployment
214 of a web portal aimed at helping people suffering from diabetes by allowing
215 a remote BG estimation.

216 **3. The proposed approach**

217 A GP-based approach for estimating BG levels in diabetic patients, start-
218 ing from their IG measurements and their corresponding first derivatives is
219 devised for solving such a *symbolic regression* problem.

220 The proposed approach relies on the structure of the SR model, that is
221 the first and most widely used model trying to relate BG with IG and IG
222 derivative [17]. Nevertheless, there exist situations in which the SR model
223 does not precisely hold, for example in case of rapid changes in BG and IG
224 [28]. Thus, the approach aims at improving the SR model by covering the
225 situations where this latter is not effective. The procedure can be summarized
226 in the following three steps:

- 227 1. enrichment of patients' databases;
- 228 2. computation of IG first derivative;
- 229 3. extraction of the model through GP.

230 The first step is optional and consists of either a single or a two-level
231 enrichment. The second step calculates the discrete derivatives for the IG
232 measurements. As regards the third step, the genetic approach is employed
233 for extracting patient-oriented models customized on each diabetic subject
234 and general models by unifying the patients' data series.

235 *3.1. Database enrichment*

236 The database enrichment is needed when a database of a diabetic subject
237 collects many IG values measured every few minutes through CGMS but only
238 a few BG measurements taken only a few times per day with glucometers.
239 This situation could be a problem in calculating the IG derivative, depending
240 on the time interval between two consecutive IG measures, and extracting
241 an effective relationship between BG, IG and IG derivative. An enrichment
242 can be performed by estimating the missing BG values by means of the SR
243 model with the parameters optimized through DE [34]. In the following,
244 this model is referred as SR_{opt} . Thus, the enriched database consists of the
245 original IGs with all the corresponding BGs. These BG values comprehend
246 the truly measured BG values and the larger number of estimated BG values.

247 Obviously, this enrichment introduces a bias in the dataset as it estimates
248 the missing BGs through SR_{opt} . For this reason, this step is optional and
249 can be omitted if the original database contains a sufficient number of BG
250 measurements.

251 A further enlargement of the database can be attained by performing a
252 second enrichment before calculating the derivatives, so that these latter are
253 smaller and more precise. This necessity could arise by considering that rapid
254 variations in glucose levels in few minutes intervals can lead to excessively
255 high derivative. Thus, after the first enhancement with SR_{opt} , IG and BG
256 data points are linearly interpolated to have their values in smaller time
257 intervals. The values corresponding to this interval are used to compute the
258 derivatives. Also this second enrichment introduces a bias, as it assumes that
259 IG and BG values change linearly over time. For this reason, this step can
260 be avoided if the database includes a sufficient number of BG and IG values
261 with consecutive IG points that do not excessively differ each other.

262 3.2. Derivatives computation

The second step basically calculates the discrete derivatives for the IG measurements. To have accurate derivatives, the concentration gradient is applied as derivative to IG values for each instant t [37]:

$$\frac{di(t)}{dt} \simeq \frac{i(t + \Delta t) - i(t - \Delta t)}{2\Delta t},$$

263 where Δt is the time interval between two consecutive IG measures. If the
264 single-level enrichment with SR_{opt} is performed, the IG derivatives are equal
265 to those that are computed without the enrichment, as this latter only esti-
266 mates the missing BG values and does not influence the IG ones. Instead,
267 if also the enrichment with interpolation is employed, the IG derivatives are
268 different from those that are evaluated without the enrichment, as this latter
269 interpolates both IG and BG values. This obviously makes the derivatives
270 smaller with respect to the ones calculated without interpolation, but also
271 introduces a bias because it assumes that IG and BG vary linearly over time.

272 3.3. Model extraction

273 The solution of a regression problem consists in finding the model that
274 expresses the relationship between a dependent variable and one or more in-
275 dependent variables. An exhaustive enumeration of all the possible models
276 is impracticable due to the considerable amount of time requested to explore

277 the complete search space. Hence, it is natural to dedicate our attention
 278 to evolutionary models, such as GP, that, despite not assuring the achieve-
 279 ment of the best model, represent a viable way to discover an appropriate
 280 suboptimal solution in a reasonable amount of time.

281 Specifically, the third step basically concerns the application of GP to the
 282 (enriched or not) data series in order to find the explicit expression of the
 283 BG level at time t , i.e. $b(t)$, as a function of the two independent variables
 284 IG and its derivative at the same time, i.e., $i(t)$ and $\frac{di(t)}{dt}$, respectively.

285 GP operates on a space of potential solutions, called *individuals*, of the
 286 problem under investigation. These solutions consist of randomly gener-
 287 ated computer programs represented as tree structures. The inner nodes in
 288 any individual denote primitive functions, while the leaf nodes comprehend
 289 terminals, i.e., either variables of the problem or constant values. During
 290 the evolution, the set of these programs, i.e., the *population*, is iteratively
 291 transformed into a new population by applying genetic operators to current
 292 individual(s) probabilistically selected with the aim to improve their *fitness*
 293 *function* Φ . Such a fitness explicitly or implicitly measures the quality of
 294 the individuals. This evolution terminates when a fixed maximum number
 295 of generations g_{max} is obtained. For a detailed description of the genetic op-
 296 erators employed during the evolution, namely selection, mutation, crossover
 297 and copy, the interested reader can refer to [15].

298 For the regression problem tackled within this paper, the population will
 299 be composed by a set of regression models. Each model is encoded as a
 300 ‘formula’, represented as a tree whose nodes can entail either functions or
 301 terminals.

302 The set of terminals consists of the set of the independent variables of
 303 the problem, plus the symbol that indicates a constant value. This latter
 304 is always used in relation to a problem variable, and its value is randomly
 305 selected in a range according to the specific involved variable.

306 To numerically assess the quality of each regression model S attained
 307 during the GP execution, we have used as base fitness function the Root
 308 Mean Square Error (*RMSE*), i.e:

$$RMSE(S) = \sqrt{\frac{\sum_{i=1}^n (b_{comp}(i) - b(i))^2}{n}} \quad (2)$$

309 where $b_{comp}(i)$ represents the calculated value for the i -th item of the database
 310 by the current model S , whereas $b(i)$ is the value of the dependent variable

311 BG for the same i -th item and n is the total number of BG values col-
 312 lected in the database. With this choice the regression problem becomes a
 313 minimization problem.

314 The model extraction can regard a specific subject or a general law as
 315 described in the sections below.

316 3.3.1. Patient-oriented approach

317 The patient-oriented approach concerns the model extraction for a specific
 318 patient and utilizes only the subject’s data series. Depending on whether or
 319 not the used dataset has been previously enriched, we can distinguish two
 320 situations for the fitness expression, described in the next paragraphs.

321 *Fitness for the original dataset.* In this case the database enrichment is not
 322 performed, the truly measured BG values are employed for the evaluation of
 323 the fitness function by eq. (2).

324 *Fitness for the enriched dataset.* When the database enrichment is carried
 325 out, to avoid a bias towards the BG values estimated with SR_{opt} in the model
 326 extraction, a fitness function with a correction factor p_m has been devised.
 327 Specifically, the fitness is a weighted sum of two sub-fitness functions, i.e.,
 328 $RMSE_c$ and $RMSE_m$:

$$\Phi = p_m \cdot RMSE_c + (1 - p_m) \cdot C \cdot RMSE_m \quad (3)$$

329 where $RMSE_c$ is the error estimated on the computed BG values, while
 330 $RMSE_m$ is the error evaluated on the measured BG values. The correction
 331 factor is given by $p_m = \frac{n_m}{n_t}$, where n_m is the number of the measured values
 332 and n_t is the total number of values (computed and measured ones) in the
 333 dataset. The constant C is an additional correction coefficient and can be
 334 tuned according to the proportions between the measured and the estimated
 335 BG values. The choice for the correction factors p_m and C in eq. (3) is
 336 due to the fact that the number of measured BG values is very small with
 337 respect to the number of estimated values. Therefore, as $RMSE_c$ weights
 338 much more than $RMSE_m$, to avoid a bias towards the BGs estimated by
 339 SR_{opt} , the correction factors are inversely proportional to the weights of their
 340 respective sub-fitness functions.

341 3.3.2. General approach

342 The general approach unifies all the patients’ datasets in a unique database
 343 used to extract a relationship between $b(t)$ and the depending variables $i(t)$

344 and $\frac{di(t)}{dt}$. Two kinds of global fitness functions are proposed: an overall fit-
 345 ness and a mean one, both described in the next paragraphs. The expression
 346 of these fitness functions takes into account the fact that the database has
 347 not been enriched as it contains a sufficient number of truly measured BG
 348 values.

349 *Fitness as an overall RMSE.* As the database has not been previously en-
 350 riched, the global fitness coincides with the RMSE (eq. (2)) computed on
 351 all the patients. This kind of fitness treats each data point as contributing
 352 equally to the function.

353 *Fitness as a mean of patients' fitnesses.* Another possible expression for the
 354 global fitness function is a weighted mean, i.e.:

$$\Phi = \frac{\sum_k^P w_k \cdot \Phi_k}{\sum_k^P w_k} \quad (4)$$

355 where Φ_k and w_k are the fitness and the weight of the k -th patient, respec-
 356 tively. In particular, Φ_k involves the evaluation of the RMSE according to eq.
 357 (2). Furthermore, $w_k = n_{t,k}$ is the total number of BG values in the dataset
 358 of the k -th subject while P is the total number of patients. Differently from
 359 the previous one, this approach considers the fact that patients with more
 360 data points in the dataset contribute more than others.

361 4. Experimental findings

362 4.1. The database

363 The real-world database, containing anonymized datasets of Type-1 dia-
 364 betic patients, was received from the Diabetology Center at the Pilsen Uni-
 365 versity. The original database comprises 6 different patients, their IDs being
 366 1 to 6 respectively. Each patient comprises several time segments. A time
 367 segment is a period in which the patient were wearing a CGMS. The dataset
 368 information for each patient is shown in Table 1. In total, there are 184
 369 time segments which include 424 BGs and 45,599 IGs. The IG values are
 370 taken with the Medtronic Minimed 640G CSIIS, equipped with an Enlite
 371 CGMS, at an interval of $\Delta t = 5$ minutes. In the experiments, the patient
 372 with ID 3 has been excluded due to sensor anomalies occurred during the
 373 data collection.

Table 1: Dataset information for each patient. The excluded patient is evidenced in italic.

Patient ID	Segments	BGs	IGs
1	9	38	3,082
2	30	76	9,410
3	<i>37</i>	<i>81</i>	<i>9,337</i>
4	32	77	8,446
5	38	76	7,662
6	38	76	7,662

374 *4.2. GP environment and parameters*

375 A tool executing GP and running in the MATLAB environment, i.e.,
 376 GPTIPS [38], has been employed to perform all the experiments reported
 377 throughout this section. It applies a type of symbolic regression called *multi-*
 378 *gene symbolic regression* that evolves linear combinations of the transforma-
 379 tions of the input variables.

380 Typically, symbolic regression is performed by using GP to evolve a pop-
 381 ulation of trees each of which encodes a mathematical equation. In contrast,
 382 in multigene symbolic regression, each member of the GP population, that
 383 is a candidate solution, is a weighted linear combination of GP trees. Multi-
 384 gene regression GP can be more accurate and efficient than standard GP
 385 for modeling problems [39], so it is used in the proposed approach. For the
 386 GP purpose, the chosen method of initialization is the ramped half-and-half.
 387 Then, tournament selection, subtree crossover and subtree mutation are cho-
 388 sen as strategies for the three main genetic operations. The terminal set
 389 is given by the IG and its derivative, which are the independent variables,
 390 to find the expression of the dependent variable BG. Table 2 reports the
 391 function set used within all the experiments.

Table 2: The set of the functions along with the corresponding symbols.

Symbol	Description
+	Addition
-	Subtraction
*	Multiplication
/	Protected division (is 1 if the denominator is 0)

392 The resulting primitive set guarantees type consistency and evaluation
 393 safety, as all the functions are type-consistent and do not throw exceptions,
 394 while the constants are all positive numeric values. Furthermore, it also
 395 ensures sufficiency, because the primitives are capable of expressing a solution
 396 to the regression problem, as we know from the SR model. As explained in
 397 Sect. 3.3, RMSE has been used as the fitness function.

398 After a preliminary tuning phase, the GP control parameters have been
 399 set as shown in Table 3. The termination criterion is the reaching of either
 400 the maximum number of generations or a fitness equal to 0.003.

Table 3: Settings of the GP control parameters

Parameter	Value
Population size	500
Maximum number of generations	300
Tournament size	30
Mutation rate	0.1
Crossover rate	0.9
Copy rate	0
Maximum tree depth	4
Maximum number of tree nodes	8
Subtrees per solution	2

401 We have subdivided our experiments into two parts. In the former, we
 402 have used a personalized approach, so that the goal has been to find the best
 403 model for all the subjects by using the enriched dataset with interpolation
 404 as described in Sect. 3.1. The relative findings are shown and commented
 405 in Sect. 4.3. In the latter part, instead, we have aimed at finding one
 406 general model that could work well by using both the global fitness functions
 407 described in Sect. 3.3.2. To this end, we have unified the dataset of all the
 408 five subjects by using the original enriched datasets without interpolation.
 409 These last experiments are described and analyzed in Sect. 4.4.

410 The estimation of BG values of the enriched database is carried out by
 411 means of the DE algorithm. The strategy used is the DE/rand/1/bin [32].
 412 The DE parameters values have been determined by a preliminary tuning
 413 as follows: the population size equal to 50, the maximum number of gen-
 414 erations equal to 200, the scale factor and the crossover ratio equal to 0.85
 415 and 1, respectively. The best outcome of the DE algorithm over 25 runs has
 416 furnished the ensuing values for the Steil-Rebrin parameters: $g = 0.98$ and
 417 $\tau = 0.02$. These values have been used to enrich the dataset with the missing
 418 BG values. As already explained, the truly measured BG are left unchanged.

419 The best resulting models of the different experiments are presented along
 420 with the tables of the relative errors with respect to the measured BG values,
 421 and the Clarke Error Grid analysis (CEG) [24] both for the personalized
 422 (patient-oriented) data and for the unified data treatment.

423 Throughout these experiments, the GP approach is compared with two
 424 other methodologies, namely IGBG that utilizes the BG estimation provided
 425 by the CGMS through simple regression models thus ignoring the actual BG
 426 dynamics and variations, and SR_{opt} that is the SR model with the parameters

427 optimized through DE [34].

428 4.3. Patient-oriented models

429 In the patient-oriented procedure, the data of all the single patients are
430 extracted from the original database. Due to the available original data being
431 made up of collections of many IGs and few BGs, each patient’s data series
432 is enhanced according to the enrichments described in Sect. 3.1. In other
433 words, the first enrichment is the computation of the missing BGs for every
434 5 minutes through SR_{opt} , while the second one is the linear interpolation of
435 the IGs and enriched BGs for every minute. The derivatives are computed
436 on the enhanced data and the GP is then carried out to discover the model.

437 The GP applied on this enhanced dataset with interpolation is named
438 $GP_{E,I}$ (E stands for enrichment, i.e., the database enhancement through
439 SR_{opt} , and I for the interpolation). Each patient’s dataset is divided into a
440 *training* and a *test* sets, containing the 70% and 30% of the ordered data,
441 respectively. The training set is used for learning the model and the test set
442 for evaluating its performance. A validation set is not taken into account
443 due to the fact that there is a limited amount of available BG measurements.
444 The fitness function is a weighted RMSE (eq. (3)), where the constant C
445 is set to 10 after a preliminary tuning. For each patient, 20 runs have been
446 performed.

447 Although the model extraction has been performed for all the five single
448 patients, for the sake of conciseness, as an example in the following para-
449 graphs we report only the model and the results for the patients with IDs 1,
450 4 and 6. Lastly, a discussion evaluates the obtained results.

451 *Patient 1.* The inferred model for the patient with ID 1 is the following:

$$b_{comp}(t) = 1.21 \cdot i(t) + 6.62 \cdot \frac{di(t)}{dt} - 1.21 \cdot 10^{-4} \cdot i(t)^2 \cdot \frac{di(t)}{di} - \quad (5) \\ - 7.18 \cdot 10^{-4} \cdot i(t)^2 - 14.56$$

452 The frequency of relative errors for this first patient is shown in Table
453 4. For the GP approach the 88% of the training items and the 75% of the
454 testing items have a relative error lower than 5%. Moreover, 100% of all the
455 items present a relative error lower than 20%. Instead, IGBG and SR_{opt}
456 on the training set never reach the 100% of items, while on the test set they
457 perform better than GP only for a relative error lower than 5%.

Table 4: Frequency of relative errors for patient with ID 1 in GP_{E,I}, IGBG and SR_{opt}.

Relative error	GP _{E,I}		IGBG		SR _{opt}	
	Training	Test	Training	Test	Training	Test
< 0.05	0.88	0.75	0.72	0.83	0.85	0.92
< 0.10	0.96	1	0.84	1	0.88	1
< 0.15	0.96	1	0.88	1	0.92	1
< 0.20	1	1	0.92	1	0.96	1
< 0.25	1	1	0.96	1	0.96	1
< 0.30	1	1	0.96	1	0.96	1
< 0.35	1	1	0.96	1	0.96	1
< 0.40	1	1	0.96	1	0.96	1
< 0.45	1	1	0.96	1	0.96	1
< 0.50	1	1	0.96	1	0.96	1

458 Figure 1 depicts the CEGs for this patient on the entire dataset: at top-
459 left the GP_{E,I} approach, at top-right the IGBG, at the bottom the SR_{opt}. We
460 can note that the concentrations estimated by the proposed GP fall in zone
461 A, while the other approaches present a point between zones B and D.

462 *Patient 4.* The model for the patient with ID 4 is:

$$b_{comp}(t) = 1.02 \cdot i(t) + 7.06 \cdot \frac{di(t)}{dt} - 0.03 \cdot i(t) \cdot \frac{di(t)}{dt} + 0.03 \cdot \left(\frac{di(t)}{dt} \right)^2 + 0.34 \quad (6)$$

463 Table 5 reports the frequency of relative errors for this patient. For the
464 GP_{E,I} approach, the 60% of training and the 68% of test items have a relative
465 error lower than 5%. GP_{E,I} training reaches 100% items with relative error
466 lower than 25%, while IGBG training and SR_{opt} training never achieve this
467 percentage. Moreover, GP_{E,I} Test reaches 100% of items with 15% of relative
468 error while IGBG Test attains 100% only for a relative error of 45% and SR_{opt}
469 Test reaches 100% for a relative error of 35%.

470 Figure 2 illustrates the CEGs for such a patient on the complete dataset:
471 all the points estimated by GP_{E,I} fall within zone A, except for two points on
472 the borders between zones A and B, and A and D respectively. We can note
473 that the points are concentrated in the area near the bisector, thus meaning
474 that the predictions are accurate. This is a very good result if compared with
475 the other two strategies. Indeed, for IGBG and SR_{opt}, several points fall in
476 zones B and D and exhibit a sparse behaviour, thus indicating less accurate
477 BG estimations or even mispredictions.

Figure 1: CEGs for patient 1. Top-left: $GP_{E,I}$, top-right: IGBG, bottom: SR_{opt} .





Table 5: Frequency of relative errors for the patient with ID 4 in $GP_{E,I}$, IGBG and SR_{opt} .

Relative error	$GP_{E,I}$		IGBG		SR_{opt}	
	Training	Test	Training	Test	Training	Test
< 0.05	0.60	0.68	0.64	0.55	0.56	0.73
< 0.10	0.91	0.91	0.89	0.73	0.89	0.86
< 0.15	0.95	1	0.96	0.86	0.92	0.91
< 0.20	0.98	1	0.96	0.91	0.92	0.91
< 0.25	1	1	0.96	0.91	0.95	0.91
< 0.30	1	1	0.98	0.91	0.96	0.91
< 0.35	1	1	0.98	0.95	0.96	1
< 0.40	1	1	0.98	0.95	0.96	1
< 0.45	1	1	0.98	1	0.96	1
< 0.50	1	1	0.98	1	0.98	1

478 *Patient 6.* The model for the patient with ID 6 is:

$$b_{comp}(t) = 0.88 \cdot i(t) + 5.50 \cdot \frac{di(t)}{dt} + 10.61 + 3.69 \cdot 10^{-4} \cdot \left(i(t) + \frac{di(t)}{dt} \right)^2 \quad (7)$$

Figure 2: CEGs for the patient with ID 4. Top-left: $GP_{E,I}$, top-right: IGBG, bottom: SR_{opt} .



479 The frequency of relative errors for such a patient is shown in Table 6.
 480 As we can see, the 59% of the $GP_{E,I}$ training items and the 74% of the $GP_{E,I}$
 481 testing items have a relative error lower than 5%, which is better than the
 482 corresponding values of IGBG and SR_{opt} . Again, $GP_{E,I}$ training and $GP_{E,I}$
 483 Test reach the 100% items at lower relative errors compared with IGBG and
 484 SR_{opt} approaches.

485 Figure 3 outlines the CEGs for this patient on the total dataset. As in
 486 the previous cases, it is possible to observe that almost the totality of the
 487 estimations done by $GP_{E,I}$ is located in zone A and just two points fall in zone
 488 B. The other two methods exhibit various and sparse points in zone B, and
 489 this means that they are less accurate than $GP_{E,I}$. Moreover, in the CEGs
 490 of IGBG and SR_{opt} the points assume a sparse behaviour, while the $GP_{E,I}$
 491 points are more concentrated along the graph bisector, thus representing a


492 better estimation.

Table 6: Frequency of relative errors for the patient with ID 6 in $GP_{E,I}$, IGBG and SR_{opt} .

Relative error	$GP_{E,I}$		IGBG		SR_{opt}	
	Training	Test	Training	Test	Training	Test
< 0.05	0.59	0.74	0.43	0.42	0.5	0.42
< 0.10	0.93	0.79	0.70	0.68	0.75	0.75
< 0.15	0.93	0.79	0.84	0.84	0.88	0.79
< 0.20	1	0.89	0.93	0.84	0.92	0.88
< 0.25	1	0.95	0.93	0.89	0.96	0.88
< 0.30	1	0.95	1	0.89	1	0.92
< 0.35	1	1	1	0.89	1	0.92
< 0.40	1	1	1	0.95	1	1
< 0.45	1	1	1	0.95	1	1
< 0.50	1	1	1	1	1	1

493 *Discussion.* For all the scenarios, the model discovered by $GP_{E,I}$ show a pro-
494 portional dependency of $b_{comp}(t)$ on $i(t)$ and $\frac{di(t)}{dt}$, thus recalling the SR model
495 [17]. The constants that multiply $i(t)$ are in the range 0.88 – 1.21, whereas
496 the constants that multiply $\frac{di(t)}{dt}$ are in the range 5.17 – 7.05. Each model
497 differs from the other ones in the correction factors and biases depending on
498 the specific case. These factors improve the basic SR model which fails in
499 computing the $i(t)$ derivatives in case of rapid glucose variations. In fact,
500 in the tables of relative errors, $GP_{E,I}$ generally reaches higher percentages
501 of items for the same relative error values, when compared with IGBG and
502 SR_{opt} . Also, the 100% of items is achieved by $GP_{E,I}$ at lower relative er-
503 rors with respect to the other two methods. From a medical viewpoint, it
504 is to point out that the CEGs report very good results for the proposed GP
505 methodology in all the patients, as almost the totality of the estimated con-
506 centrations falls in zone A, except for a small number of points in zone B.
507 In fact, zones A and B represent accurate clinical estimations with a corre-
508 sponding high probability of correct clinical treatments. Instead, IGBG and
509 SR_{opt} show many more points in zone B and even some points in D. This
510 latter zone represents estimations that are far from being acceptable and
511 could lead to incorrect clinical treatments. The obtained findings imply that
512 the evolutionary approach allows better estimations than other methods and
513 thus could be effectively employed in AP devices.

Figure 3: CEGs for the patient with ID 6. Top-left: $GP_{E,I}$, top-right: IGBG, bottom: SR_{opt} .



514 4.4. General model on enriched database

515 In the previous section, we have presented the patient-oriented approach
 516 that is customized for the specific diabetic subject. However, it can be useful
 517 to find a general law able to describe the glycemia behaviour as a function
 518 of time independently on the target patient. This could be employed in
 519 those kinds of healthcare medical devices that have to be general-purpose
 520 and adaptable to specific subjects. The general model extracted from the
 521 enhanced database takes into account the data series of the patients with
 522 IDs 1, 2, 4, 5 and 6. These data are unified and then enriched through
 523 the SR_{opt} approach. Indeed, as mentioned before, the original data is a col-
 524 lection of several IG measurements and a small amount of real BG ones.
 525 Therefore, SR_{opt} estimates the missing BG values. After the enhancement,
 526 the IG derivatives are computed. In particular, as the database is a collection

527 of data from several time segments of different subjects, the IG derivative
528 between two IG points belonging to different patients is not truly measured.
529 Indeed, the final segment of a patient and the initial segment of the next
530 one differ from each other in a period of time much longer than 5 minutes.
531 To avoid extremely high and inaccurate derivatives in those discontinuities,
532 $\frac{di(t)}{dt}$ is set to 0 if t is the first or the last index of the initial and last time
533 segment of two consecutive patients, otherwise it equals the gradient. A sec-
534 ond level enrichment, i.e. through interpolation, has not been considered as
535 the five patients' unified database contains a sufficient number of measure-
536 ments. The GP is carried out with 20 runs on the enriched database. For
537 the GP purpose, the unified series of the five patients is divided into three
538 sets, i.e. *training*, *validation* and *test* sets, containing the 60% (first three
539 patients), 22% (fourth patient) and 18% (last patient) of the ordered data,
540 respectively. The training set is used to fit the model. The validation set
541 provides an unbiased evaluation of the model fitting. Finally, the test set is
542 used to assess the quality of the best model (in terms of best fitness achieved
543 over the previous sets).

544 In this general method, two fitness functions are proposed, namely an
545 overall fitness (eq. (3)), and a mean fitness (eq. (4)). In both cases, the con-
546 stant C appearing in their formulas is set to 10 on the basis of a preliminary
547 tuning phase. The GP approach using the overall fitness is referred to as
548 $GP_{E,all}$, while the one using the mean fitness is referred to as $GP_{E,mean}$. The
549 extracted models are outlined in the following paragraphs, together with a
550 final discussion that compares GP-based models with IGBG and SR_{opt} mod-
551 els.

552 *Fitness as an overall weighted RMSE.* The model in case of using an overall
553 weighted fitness, with the form of the eq. (3), is:

$$b_{comp}(t) = 1.05 \cdot i(t) + 0.93 \cdot \frac{di(t)}{dt} + 4.2 \cdot 10^{-8} \cdot \left(i(t) \cdot \frac{di(t)}{dt} \right)^2 - 4.72 \quad (8)$$

554 *Fitness as a mean of patients' fitness.* The model in case of using a weighted
555 mean fitness, with the form of the Equation (4), is the following:

$$b_{comp}(t) = 1.05 \cdot i(t) + 1.05 \cdot \frac{di(t)}{dt} - 4.78 - 3.901 \cdot 10^{-8} \cdot i(t)^3 \cdot \frac{di(t)}{dt} + \\ + 3.901 \cdot 10^{-8} \cdot \left(i(t) \cdot \frac{di(t)}{dt} \right)^2 \quad (9)$$

556 To evaluate the proposed general models, the frequency of relative errors
 557 is shown in Table 7, together with IGBG and SR_{opt} .

Table 7: Frequency of relative errors for the general model in $GP_{E,all}$, $GP_{E,mean}$, IGBG and SR_{opt} for the training, validation (Val) and test sets.

Relative error	$GP_{E,all}$			$GP_{E,mean}$			IGBG			SR_{opt}		
	Training	Val	Test	Training	Val	Test	Training	Val	Test	Training	Val.	Test
< 0.05	0.64	0.57	0.59	0.63	0.57	0.58	0.59	0.41	0.42	0.59	0.47	0.48
< 0.1	0.88	0.88	0.89	0.88	0.87	0.87	0.84	0.73	0.70	0.84	0.76	0.74
< 0.15	0.95	0.89	0.90	0.95	0.89	0.90	0.93	0.85	0.84	0.92	0.86	0.85
< 0.2	0.99	0.95	0.94	0.98	0.95	0.94	0.95	0.91	0.90	0.95	0.91	0.91
< 0.25	0.99	0.99	0.98	0.99	0.99	0.98	0.96	0.93	0.92	0.95	0.94	0.94
< 0.3	0.99	0.99	0.99	0.99	0.99	0.98	0.97	0.97	0.97	0.97	0.97	0.97
< 0.35	1	0.99	0.98	1	0.99	0.98	0.98	0.97	0.97	0.98	0.97	0.97
< 0.4	1	1	1	1	1	1	0.98	0.99	0.98	0.98	1	1
< 0.45	1	1	1	1	1	1	0.99	0.99	0.98	0.98	1	1
< 0.5	1	1	1	1	1	1	0.99	1	1	0.99	1	1


558 Table 8 depicts the percentages of points falling in the respective zones
 559 of the CEGs for the compared methods on the entire database.

Table 8: Percentages of points falling in the zones of the CEG for the general model in $GP_{E,all}$, $GP_{E,mean}$, IGBG and SR_{opt} .

Zone	$GP_{E,all}$			$GP_{E,mean}$			IGBG			SR_{opt}		
	Training	Val	Test	Training	Val	Test	Training	Val	Test	Training	Val.	Test
A	98.95	94.67	93.65	97.89	94.67	93.65	95.26	90.67	90.48	95.48	91.03	90.91
B	1.05	5.33	6.35	2.11	5.33	6.35	3.68	8	9.52	3.02	7.69	9.09
A+B	100	100	100	100	100	100	98.94	98.67	100	98.50	98.71	100
C	0	0	0	0	0	0	0	0	0	0	0	0
D	0	0	0	0	0	0	0.91	1.05	1.34	1.51	1.28	0
E	0	0	0	0	0	0	0	0	0	0	0	0

560 *Discussion.* As it can be seen from the extracted models shown in eqs. 8 and
 561 9, according to the employed fitness function, the proposed GP approach is
 562 capable of reconstructing different general laws describing the BG trend as
 563 a function of IG and its derivative. These laws rely on the SR model but
 564 improve it with appropriate correction factors and constants that are not
 565 taken into account by IGBG and SR_{opt} . In fact, IGBG considers the IG
 566 trend as if it was the exact BG trend, thus ignoring the real BG dynamics
 567 and variations, while SR_{opt} does not hold in case of rapid BG changes, as

Figure 4: CEGs for the general model on enhanced dataset. Top-left: $GP_{E,all}$, top-right: $GP_{E,mean}$, bottom-left: IGBG, bottom-right: SR_{opt} .



568 we know from theory. Moreover, from the Table 7, we can observe that
 569 generally $GP_{E,all}$ and $GP_{E,mean}$ reach similar percentages of items for the
 570 same relative error, percentages that are higher than those attained by the
 571 other two strategies. For example, for a relative error less than 5%, $GP_{E,all}$
 572 reaches 64% in training, 57% in validation and 59% in test, while $GP_{E,mean}$
 573 achieves 63%, 57% and 58%, respectively. For the same relative error, IGBG
 574 reaches 59%, 41% and 42% while SR_{opt} reaches 59%, 47% and 48% of items.
 575 Furthermore, the GP approaches reach 100% of training items for a relative
 576 error less than 35%, that is a percentage achieved by IGBG and SR_{opt} at
 577 higher relative errors. The effectiveness of the GP approaches is confirmed

578 by their small RMSEs. The best RMSE values for the general models on the
 579 enriched database are reported in Table 9.

Table 9: Best RMSE for the general models on the enriched database.

	$GP_{E,all}$	$GP_{E,mean}$	IGBG	SR_{opt}
Training	10.61	10.64	18.05	15.58
Validation	10.35	10.43	17.25	15.50
Test	10.75	10.82	18.47	15.83

580 As we can see from Table 8, for the GP methodologies, almost the totality
 581 of the predictions falls in zone A except for few points in B. Instead, IGBG
 582 and SR_{opt} present more points in zone B and also a percentage of points
 583 in zone D, thus revealing dangerous mispredictions. It is to remark that
 584 the ability of the GP approach to avoid incorrect estimates in zone D is
 585 of a prominent importance from a medical viewpoint. In fact, erroneous
 586 predictions in this latter zone could have fatal consequences for diabetic
 587 patients subject both to manual and to automatic treatment of the insulin
 588 regulation. Furthermore, it is worth noting that both the GP methods reach
 589 a greater percentage of predicted BG values in zone A than IGBG and SR_{opt}
 590 on the test set, as it is possible to observe from Fig. 4. The picture shows
 591 the CEGs in the different situations: at the top-left $GP_{E,all}$, at the top-right
 592 $GP_{E,mean}$, at the bottom-left IGBG, and at the bottom-right SR_{opt} .

593 In conclusion, the proposed GP approach outperforms IGBG and SR_{opt}
 594 both from a numerical and, even more importantly, from a medical viewpoint.

595 5. Conclusions and future works

596 The present paper has introduced an innovative evolutionary methodol-
 597 ogy for estimating BG from IG measurements and their derivatives. Specifi-
 598 cally, through the GP, the proposed approach derives a law able to forecast
 599 the BG trend of diabetic subjects by starting from their past BG and IG
 600 measurements. To demonstrate the effectiveness of this method, several ex-
 601 periments have been carried out over a real-world database containing both
 602 BG and IG measurements from five diabetic patients. The final goal of these
 603 experiments has been the extraction of an explicit relationship between BG,
 604 IG and IG derivative at the same time under the form of a mathematical
 605 expression. The excerpted model could be the core of the knowledge base of
 606 intelligent medical devices, such as the AP.

607 Experiments have been performed on the personalized datasets enriched
608 through the SR model and the interpolation, and on the global enriched
609 database without interpolation. These experiments have allowed finding both
610 patient-oriented models and general models able to describe the glycemia be-
611 haviour as a function of time independently of a specific patient. The person-
612 alized models could be applicable in medical devices that have to precisely
613 fit the individual glycemetic dynamics. The global relationship could be em-
614 ployed in those kinds of healthcare devices that have to be general purpose
615 and adaptable to the target subjects.

616 The findings have shown a similarity between the performances of the
617 GP on personalized and global data. In fact, in all the extracted models
618 it is evident a proportional dependency of BG on IG and IG derivative at
619 the same time. This behaviour recalls the basic SR model that has been
620 the reference model for the present work. However, each extracted model
621 differs from the other ones in correction factors and biases depending on
622 the particular situation. These factors improve the SR model, which in fact
623 does not hold in case of rapid glucose variations. Furthermore, the results
624 also prove that it can be useful to enrich the data through estimation of
625 the missing BGs with the SR model and, in case of necessity, with linear
626 interpolation.

627 Throughout the experiments, the effectiveness of the proposed evolution-
628 ary approach has been ascertained by comparison with two state-of-the-art
629 methods, namely IGBG and SR_{opt} under different points of view and with
630 different methods of analysis, like the frequency of the relative errors, the
631 CEGs and the RMSE evaluation. All the results show that the GP vari-
632 ants always outperform the other two approaches, in terms of quality of the
633 BG estimations. Moreover, it is to point out that the performance of the
634 GP is particularly valid from a medical viewpoint since it permits avoiding
635 dangerous inaccuracies in BG estimations.

636 In conclusion, the presented GP methodology could be useful in different
637 contexts and for several purposes to improve the future diabetes healthcare
638 and the quality of life of diabetic people.

639 In the future works we intend to investigate the correction factors dis-
640 covered by the GP-based models to determine which factors are specific to
641 the patient, and which ones model CGMS's errors. Further future develop-
642 ments include the use of evolutionary-devised models in a clinical study to
643 estimate the BG values of the involved subjects. This implies an extension
644 of the methodology under different aspects. The proposed patient-oriented

645 approach could be extended to take into account other interesting variables
646 as the carbohydrate intakes and the insulin boluses of the subject, in or-
647 der to perform a prediction of future glycemic levels. After supplementary
648 experiments, it could be exploited in forthcoming special-purpose medical
649 devices for the diabetes healthcare. On the other hand, the general approach
650 could be expanded to larger datasets to extract a more and more accurate
651 general relationship. This latter could be utilized in general-purpose devices
652 for the estimation of the BG trend without dealing with the cost related to
653 the necessity of learning over each subject.

654 **Acknowledgements**

655 This publication was partially supported by the project LO1506 of the
656 Czech Ministry of Education, Youth and Sports.

657 **References**

- 658 [1] World Health Organization, Diabetes fact sheet n. 312 (October 2013).
- 659 [2] F. Bonnet, A. J. Scheen, Impact of glucose-lowering therapies on risk of
660 stroke in type 2 diabetes, *Diabetes & Metabolism* 43 (4) (2017) 299–313.
- 661 [3] N. Glezeva, M. Chisale, K. McDonald, M. Ledwidge, J. Gallagher, C. J.
662 Watson, Diabetes and complications of the heart in sub-saharan africa:
663 An urgent need for improved awareness, diagnostics and management,
664 *Diabetes Research and Clinical Practice* 137 (2018) 10–19.
- 665 [4] World Health Organization, Global report on diabetes (2016).
- 666 [5] S. K. Vashist, Continuous glucose monitoring systems: a review, *Diag-
667 nostics* 3 (4) (2013) 385–412.
- 668 [6] B. Kovatchev, S. Anderson, L. Heinemann, W. Clarke, Comparison of
669 the numerical and clinical accuracy of four continuous glucose monitors,
670 *Diabetes Care* 31 (2008) 1160–1164.
- 671 [7] E. R. Damiano, F. H. El-Khatib, H. Zheng, D. M. Nathan, S. J. Rus-
672 sell, A comparative effectiveness analysis of three continuous glucose
673 monitors, *Diabetes Care* 36 (2013) 251–259.

- 674 [8] M. P. Christiansen, S. K. G. R. Brazg, B. W. Bode, T. S. Bailey, R. H.
675 Slover, A. Sullivan, S. Huang, J. Shin, S. W. Lee, F. R. Kaufman, Ac-
676 curacy of a fourth-generation subcutaneous continuous glucose sensor,
677 *Diabetes Technol. Ther.* 2017 19 (8) (2017) 446–456.
- 678 [9] S. Zavitsanou, J. B. Lee, J. E. Pinsker, M. M. Church, F. J. Doyle,
679 E. Dassau, A personalized week-to-week updating algorithm to improve
680 continuous glucose monitoring performance, *J Diabetes Sci Technol.*
681 2017 Nov;11(6):1070-1079 11 (6) (2017) 1070–1090.
- 682 [10] Y. H. Baek, H. Y. Jin, K. A. Lee, S. M. Kang, W. J. Kim, M. G. Kim,
683 J. H. Park, S. W. Chae, H. S. Baek, T. S. Park, The correlation and
684 accuracy of glucose levels between interstitial fluid and venous plasma
685 by continuous glucose monitoring system, *Korean Diabetes J.* 34 (2010)
686 350–358.
- 687 [11] P. Rossetti, J. Bondia, J. Vehí, C. Fanelli, Estimating plasma glucose
688 from interstitial glucose: the issue of calibration algorithms in commer-
689 cial continuous glucose monitoring devices, *Sensors* 10 (2010) 10936–
690 10952.
- 691 [12] G. Aleppo, K. J. Ruedy, T. D. Riddlesworth, D. F. Kruger, A. L. Peters,
692 I. Hirsch, R. M. Bergenstal, E. Toschi, A. J. Ahmann, V. N. Shah, M. R.
693 Rickels, B. W. Bode, A. Philis-Tsimikas, R. Pop-Busui, H. Rodriguez,
694 E. Eyth, A. Bhargava, C. Kollman, R. W. Beck, REPLACE-BG: A ran-
695 domized trial comparing continuous glucose monitoring with and with-
696 out routine blood glucose monitoring in adults with well-controlled type
697 1 diabetes., *Diabetes Care* 40 (4) (2017) 538–545.
- 698 [13] J. I. Hidalgo, J. M. Colmenar, G. Kronberger, S. M. Winkler, O. Gar-
699 nica, J. Lanchares, Data based prediction of blood glucose concentra-
700 tions using evolutionary methods, *J Med Syst.* 2017 41 (9) (2017) 142.
- 701 [14] I. De Falco, A. Della Cioppa, A. Giuliano, T. Koutny, M. Krcma, U. Sca-
702 furi, E. Tarantino, An evolutionary methodology for estimating blood
703 glucose levels from interstitial glucose measurements and their deriva-
704 tives, in: *Proceedings of the Third IEEE Workshop on ICT Solutions*
705 *for Health, Natal, Brazil, June 25-28, 2018.* To be published.
- 706 [15] J. Koza, *Genetic programming: on the programming of computers by*
707 *means of natural selection*, Vol. 1, MIT Press, 1992.

- 708 [16] A. Borrelli, I. De Falco, A. Della Cioppa, M. Nicodemi, G. Trautteur,
709 Performance of genetic programming to extract the trend in noisy data
710 series, *Physica A* 370 (1) (2006) 104–108.
- 711 [17] K. Rebrin, G. Steil, W. van Antwerp, J. Mastrototaro, Subcutaneous
712 glucose predicts plasma glucose independent of insulin: implications for
713 continuous monitoring, *Am. J. Physiol.* 277 277 (1999) E561–E571.
- 714 [18] R. Hovorka, V. Canonico, L. J. Chassin, U. Haueter, M. Massi-
715 Benedetti, M. Orsini Federici, T. R. Pieber, H. C. Schaller, L. Schaupp,
716 T. Vering, M. E. Wilinska, Nonlinear model predictive control of glucose
717 concentration in subjects with type 1 diabetes, *Physiol. Meas.* 25 (2004)
718 905–920.
- 719 [19] A. Makroglou, J. Li, Y. Kuang, Mathematical models and software tools
720 for the glucose-insulin regulatory system and diabetes: an overview,
721 *Appl. Numer. Math.* 56 (2006) 559–573.
- 722 [20] P. Dua, F. J. Doyle, E. N. Pistikopoulos, Model-based blood glucose
723 control for type 1 diabetes via parametric programming, *IEEE Trans-*
724 *actions on Biomedical Engineering* 53 (8) (2006) 1478–1491.
- 725 [21] J. Kildegaard, J. Randløv, O. H. J. U. Poulsen, The impact of non-
726 model-related variability on blood glucose prediction, *Diabetes Technol.*
727 *The.* 9 (4) (2007) 363–371.
- 728 [22] A. Facchinetti, G. Sparacino, C. Cobelli, Sensors & algorithms for con-
729 tinuous glucose monitoring reconstruction of glucose in plasma from
730 interstitial fluid continuous glucose monitoring data role of sensor cali-
731 bration, *J. Diabetes Sci. Technol.* 1 (2007) 617–623.
- 732 [23] Y. Leal, W. Garcia-Gabin, J. Bondia, E. Esteve, W. Ricart, J. M.
733 Fernandez-Real, J. Vehí, Real-time glucose estimation algorithm for con-
734 tinuous glucose monitoring using autoregressive models, *J. Diabetes Sci.*
735 *Tech.* 4 (2) (2010) 391–403.
- 736 [24] W. L. Clarke, D. Cox, L. Gonder-Frederick, W. Carter, S. Pohl, Eval-
737 uating clinical accuracy of systems for self-monitoring of blood glucose,
738 *Diabetes Care* 10 (1987) 622–628.

- 739 [25] C. Pérez-Gandía, A. Facchinetti, G. Sparacino, C. Cobelli, E. Gómez,
740 M. Rigla, A. de Lieiva, M. E. Hernando, Artificial neural network algo-
741 rithm for online glucose prediction from continuous glucose monitoring,
742 *Diabetes Technol. The.* 12 (1) (2010) 81–88.
- 743 [26] T. Koutny, Estimating reaction delay for glucose level prediction, *Med.*
744 *Hypotheses* 77 (6) (2011) 1034–1037.
- 745 [27] T. Koutny, Prediction of interstitial glucose level, *IEEE Trans. Inf. Tech-*
746 *inol. Biomed.* 16 (2012) 136–142.
- 747 [28] T. Koutny, Blood glucose level reconstruction as a function of transcap-
748 illary glucose transport, *Comput. Biol. Med.* 53 (2014) 171–178.
- 749 [29] S. Del Favero, A. Facchinetti, G. Sparacino, C. Cobelli, Improving ac-
750 curacy and precision of glucose sensor profiles: retrospective fitting by
751 constrained deconvolution, *IEEE Trans. Biomed. Eng.* 61 (4) (2014)
752 1044–1053.
- 753 [30] M. Rigla, G. García-Sáez, B. Pons, M. E. Hernando, Artificial intelli-
754 gence methodologies and their application to diabetes, *Format: Abstract*
755 *Send to J Diabetes Sci Technol.* 12 (2) (2018) 303–310.
- 756 [31] T. Koutny, Using meta-differential evolution to enhance a calculation of
757 a continuous blood glucose level, *Comput. Meth. Prog. Bio.* 133 (2016)
758 45–54.
- 759 [32] K. Price, R. Storn, Differential evolution, *Dr. Dobb’s J.* 22 (4) (1997)
760 18–24.
- 761 [33] I. De Falco, A. Della Cioppa, U. Scafuri, E. Tarantino, Accurate esti-
762 mate of blood glucose through interstitial glucose by genetic program-
763 ming, in: *Proceedings of the International Symposium on Computers*
764 *and Communications*, IEEE Press, 2017, pp. 284–289.
- 765 [34] I. De Falco, A. Della Cioppa, T. Koutny, M. Krema, U. Scafuri,
766 E. Tarantino, An evolutionary approach for estimating the blood glu-
767 cose by exploiting interstitial glucose measurements, in: *In Proceedings*
768 *of the Eleventh International Joint Conference on Biomedical Engineer-*
769 *ing Systems and Technologies - Workshop on Artificial Intelligence for*

- 770 Health, Vol. 5, Funchal, Madeira, Portugal, January 19-21, 2018, pp.
771 625–632.
- 772 [35] T. Koutny, M. Krcma, J. Kohout, P. Jezek, J. Varnuskova, P. Vcelak,
773 J. Strnadek, On-line blood glucose level calculation, *Procedia Comput.*
774 *Sci.* 98 (2016) 228–235.
- 775 [36] I. De Falco, A. Della Cioppa, T. Koutny, M. Krcma, U. Scafuri,
776 E. Tarantino, Genetic programming-based induction of a glucose-
777 dynamics model for telemedicine, *Journal of Network and Computer*
778 *Applications* 119 (2018) doi: 10.1016/j.jnca.2018.06.007.
- 779 [37] W. H. Press, S. A. Teukolsky, W. T. Vetterling, B. P. Flannery, *Numerical*
780 *Recipes: The Art of Scientific Computing*, 3rd Edition, Cambridge
781 University Press, 2007.
- 782 [38] D. Searson, GPTIPS: Genetic programming and symbolic regression for
783 MATLAB. <http://gptips.sourceforge.net>., 2009. (2009).
- 784 [39] A. H. Gandomi, A. H. Alavi, A new multi-gene genetic programming
785 approach to nonlinear system modeling. part i: materials and structural
786 engineering problems, *Neural Computing and Applications* 21 (1) (2012)
787 171–187.